Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Masato Ozaka

9PUBLICATIONS

50CO-AUTHORS

Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSolid tumours

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Feb 27, 2026

Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Jul 28, 2025

Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurrent Pancreatic Cancer (GENERATE, JCOG1611): A Randomized, Open-Label, Phase II/III Trial.

Akihiro Ohba, Masato Ozaka, Junki Mizusawa

|Jun 11, 2025

Impact of second-line combination chemotherapy on post-progression survival in metastatic and recurrent pancreatic cancer.

Takafumi Mie, Masato Ozaka, Takeshi Okamoto

|Apr 10, 2025

Pathological complete response following addition of durvalumab to gemcitabine and cisplatin therapy for intrahepatic cholangiocarcinoma with Lynch syndrome-associated mismatch repair deficiency.

Koshiro Fukuda, Akiyoshi Kasuga, Yasuyuki Shigematsu

|Feb 23, 2025

NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design.

Masafumi Ikeda, Takuji Okusaka, Makoto Ueno

|Dec 23, 2023

Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer.

Takeshi Okamoto, Tsuyoshi Takeda, Takafumi Mie

Pageof 2

Frequent Collaborators

3 joint publications

Takeshi Okamoto

3 joint publications

Akiyoshi Kasuga

3 joint publications

Naoki Sasahira

3 joint publications

Makoto Ueno

3 joint publications

Junji Furuse

2 joint publications

Takafumi Mie

2 joint publications

Takashi Sasaki

2 joint publications

Tsuyoshi Takeda

2 joint publications

Masafumi Ikeda

2 joint publications

Takuji Okusaka

Frequent Collaborators

3 joint publications

Takeshi Okamoto

3 joint publications

Akiyoshi Kasuga

3 joint publications

Naoki Sasahira

3 joint publications

Makoto Ueno

Top Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on : Oct 25, 2011

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on : Feb 02, 2024

See more related videos

Top Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on : May 24, 2024

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on : Oct 25, 2011

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency

Published on : Feb 02, 2024

See more related videos